Moderna and merck announce mrna-4157 (v940), an investigational individualized neoantigen therapy, in combination with keytruda(r) (pembrolizumab), demonstrated superior recurrence-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda
Mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 44% compared to keytruda alone in stage iii/iv melanoma patients with high risk of recurrence following complete resection results from the phase 2b keynote-942 trial selected for aacr press program companies will initiate a phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer cambridge, ma and rahway, nj / accesswire / april 16, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced the first presentation of detailed results from the phase 2b keynote-942/mrna-4157-p201 trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv). in the overall intention-to-treat population, adjuvant treatment with mrna-4157 (v940) in combination with keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (rfs), and reduced the risk of recurrence or death by 44% (hr=0.56 [95% ci, 0.309-1.017]; one-sided p value=0.0266) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission